Exploratory study on the impact of different doses and route of administration of exogenous progesterone in artificial endometrial preparation cycles on endometrial structure and function

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515811-22-00

Acronym

1901-VLC-014-EL

Enrollment

108

Registered

2024-07-22

Start date

2021-10-10

Completion date

2025-03-31

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

- Gene expression for the whole transcriptome (22000 genes) related to progesterone treatments response in the window of implantation. - Number of differential expressed genes between P treatment groups in comparison with its natural cycle

Interventions

DRUGPRONTOGEST 100 mg/ml soluzione iniettabile

DRUGProlutex 25 mg solución inyectable en jeringa precargada.

DRUGSeidigestan 200 mg cápsulas blandas

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
- Gene expression for the whole transcriptome (22000 genes) related to progesterone treatments response in the window of implantation. - Number of differential expressed genes between P treatment groups in comparison with its natural cycle	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026